Key result
Ketorolac linked to successful postoperative platelet suppression in aspirin-allergic patients requiring microvascular free tissue transfer.
Why the study?
Aspirin is traditionally used to inhibit platelet aggregation after microvascular surgery, but it is occasionally contraindicated, necessitating alternative agents.
Does ketorolac inhibit platelet aggregation in patients requiring microvascular free tissue transfer who are allergic to aspirin?
Case Report (n=2)
Does ketorolac inhibit platelet aggregation in patients requiring microvascular free tissue transfer who are allergic to aspirin?
Ketorolac may serve as an effective alternative for inhibiting platelet aggregation after microvascular surgery in patients with contraindications to aspirin.
No takes yet. Share an insight, caveat, or question.
Ketorolac may inhibit platelet function in aspirin-allergic free flap patients; hypothesis-generating case report requiring prospective validation.
Concannon et al. (1993) conducted a case report in Microvascular free tissue transfer (n=2). Toradol (ketorolac) was evaluated on Platelet function suppression. Toradol (ketorolac) successfully suppressed postoperative platelet function in two patients requiring microvascular free tissue transfer who were allergic to aspirin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: